Anderley Gordon

Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer.

W ten Bokkel Huinink, Martin Gore, J Carmichael et al. · Journal of Clinical Oncology · 1997 · 681 citations

Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel.

M. A. Bookman, Henric Malmström, Giorgio Bolis et al. · Journal of Clinical Oncology · 1998 · 334 citations

Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study

Anderley Gordon, N. Finkler, Robert P. Edwards et al. · International Journal of Gynecological Cancer · 2005 · 221 citations

A comparative economic analysis of pegylated liposomal doxorubicin versus topotecan in ovarian cancer in the USA and the UK

D. H. Smith, Jared Adams, Stephen Johnston et al. · Annals of Oncology · 2002 · 74 citations · Full text

Comparative Economic Analysis, Medicine, Cancer Management +8

Phase I dose escalation of paclitaxel in patients with advanced ovarian cancer receiving cisplatin: rapid development of neurotoxicity is dose-limiting.

Anderley Gordon, C. Allen Stringer, Carolyn M. Matthews et al. · Journal of Clinical Oncology · 1997 · 36 citations